Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

933
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
933
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

268
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
268
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

411
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
411
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

676
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
676
Dosage Regimen Designs: Nomograms and Tabulations01:23

Dosage Regimen Designs: Nomograms and Tabulations

305
Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
305
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

316
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
316

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of extracorporeal membrane oxygenation in immunocompromised patients: a national cohort analysis, 2018-2022.

Heart & lung : the journal of critical care·2026
Same author

Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis.

Clinical pharmacokinetics·2026
Same author

Impact of tariff on Indian AYUSH products: Evidence from top importers of India.

Journal of Ayurveda and integrative medicine·2026
Same author

The impact of pulmonary hypertension and comorbidities on in-hospital mortality in hypertrophic obstructive cardiomyopathy: A nationwide analysis from 2016 to 2021.

Heart & lung : the journal of critical care·2026
Same author

Chemotherapy-driven expression of WNT ligands in bone marrow stromal cells contributes to chemoresistance in acute lymphoblastic leukaemia.

British journal of haematology·2026
Same author

Altered cholesterol immunometabolism activates the macrophage NLRP3-inflammasome in lung fibrosis.

American journal of respiratory cell and molecular biology·2026
Same journal

Population Pharmacokinetic Modeling and Simulation to Support the Regulatory Submission of the Two-Injection Start Regimen with Aripiprazole Once-Monthly Long-Acting Injectable Intramuscular Administration in Japanese Patients with Schizophrenia or Bipolar I Disorder.

Journal of clinical pharmacology·2026
Same journal

External Evaluation of Population Pharmacokinetic Models for Factor VIII in Chinese Patients with Hemophilia A.

Journal of clinical pharmacology·2026
Same journal

How to Replace the TQT Study-The Use of Concentration-QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and Implementation.

Journal of clinical pharmacology·2026
Same journal

Genome Sequencing Enhances Precision and Clinical Utility of Pharmacogenetic Data Compared to Arrays.

Journal of clinical pharmacology·2026
Same journal

FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future Directions.

Journal of clinical pharmacology·2026
Same journal

Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

Journal of clinical pharmacology·2026
See all related articles

Related Experiment Video

Updated: Apr 7, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.7K

Reporting guidelines for population pharmacokinetic analyses.

Kevin Dykstra1, Nitin Mehrotra2, Christoffer Wenzel Tornøe3

  • 1qPharmetra LLC, Andover, MA, USA.

Journal of Clinical Pharmacology
|July 8, 2015
PubMed
Summary
This summary is machine-generated.

New guidelines standardize population pharmacokinetic (PK) reporting. These principles ensure clear communication of drug exposure analysis and its impact on drug development decisions for diverse audiences.

Keywords:
Best practicesPK reportingPopulation pharmacokineticsRegulatory submission

More Related Videos

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.9K
Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

2.4K

Related Experiment Videos

Last Updated: Apr 7, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.7K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.9K
Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

2.4K

Area of Science:

  • Pharmacometrics
  • Drug Development
  • Regulatory Science

Background:

  • Population pharmacokinetic (PK) analyses are crucial for understanding drug exposure and informing dose selection.
  • Current reporting practices lack standardization, potentially hindering effective communication and review.

Purpose of the Study:

  • To develop consolidated guiding principles for reporting population PK analyses.
  • To enhance the clarity and impact of PK reports for both technical and non-technical audiences.

Main Methods:

  • Survey of practitioners and discussions among industry, consulting, and regulatory scientists.
  • Development of a question-based approach and recommended report structure (8 sections).

Main Results:

  • Population PK analysis significantly influences identification of covariate effects and dose selection.
  • Guidelines address two main report purposes: communicating findings for decisions and documenting methods for review/reuse.
  • Identified two key audiences: technical reviewers and scientifically literate non-experts.

Conclusions:

  • The proposed guidelines aim to standardize population PK reporting, improving understanding and decision-making.
  • These principles are applicable to all pharmacometric reports, including PK/PD and simulation reports.
  • Enhances the "industrialization" of pharmacometrics for broader comprehension and utilization in drug development.